

ACCEPTANCE REVIEW MEMO (ARM)

Licensee: Ketchikan General Hospital

License No.: 50-19913-01

Docket No.: 030-19521

Mail Control No.: 471099

Type of Action: Notify

Date of Requested Action: 08-18-06

Reviewer Assigned:

ARM reviewer(s): Torres

Response	Deficiencies Noted During Acceptance Review
	<p>[] Open ended possession limits. Limit possession. Submit inventory.</p> <p>[] Submit copies of most recent leak test results.</p> <p>[] Add - delete IC license condition. Add IC paragraph in cover letter.</p> <p>[] Split license from cover letter. Add SUNSI marking to license.</p> <p>[] Ask the licensee if they have any type-amount of EPAct Material.</p>

RJTC

Reviewer's Initials: _____

Date: _____

Yes No Unrestricted release Group 2 or >: Transfer memo to FCDB within 10 days.
 Yes No Decommissioning notification should be completed within 30 days.
 Yes No Termination request < 90 days from date of expiration
 Yes No Expedite (medical emergency, no RSO, location of use/storage not on license, RAM in possession not on license, other)
 Yes No TAR needed to complete action.

Branch Chief's and/or Sr. HP's Initials: _____ Date: _____

SUNSI Screening according to RIS 2005-31

Yes No **Non-Publicly Available, Sensitive** if any item below is checked

General guidance:

- _____ RAM = or > than Category 3 (Table 1, RIS 2005-31), use Unity Rule
- _____ Exact location of RAM (whether = or > than Category 3 or not)
- _____ Design of structure and/or equipment (site specific)
- _____ Information on nearby facilities
- _____ Detailed design drawings and/or performance information
- _____ Emergency planning and/or fire protection systems

Specific guidance for medical, industrial and academic (above Category 3):

- _____ RAM quantities and inventory
- _____ Manufacturer's name and model number of sealed sources & devices
- _____ Site drawings with exact location of RAM, description of facility
- _____ RAM security program information (locks, alarms, etc.)
- _____ Emergency Plan specifics (routes to/from RAM, response to security events)
- _____ Vulnerability/security assessment/accident-safety analysis/risk assess
- _____ Mailing lists related to security response

Branch Chief's and/or Sr. HP's Initials: *RJTC* Date: 9-11-06

ADAMS # MLO42580113
 Template _____
 Date 9-15-06 QC'd by SM

Pre-Licensing Screening

Applicant Information:

Control No. 471099

Name: Ketchikan General Hospital	Type of Request: Notify Program Code(s):	
Location: AK	License No.: 50-19913-01	Docket No.: 030-19521

STEP 1—Radioactive Materials and Quantities Requested:

Instructions for Step 1: Complete Step 1 for all applications. If all your responses in Step 1 are "No" then do not complete Step 2 (Screening Criteria). Sign and date the completed step-sheet and add it as the sensitive and non-publicly available OAR in ADAMS. If a "yes" response is indicated for any item in Step 1, also complete Step 2. If the type of use is subject to a Security Order or the requirements for increased controls, complete Step 3 (Item A or Item B) without delay.	Yes or No
A. The request is from a new applicant.	N
B. NUREG-1556, Volume 20, Section 4.9 indicates a licensing site visit is needed for the requested type of use, e.g., (1) Type A broad scope license, (2) panoramic irradiator containing > 10000 curies, (3) manufacturers or distributors using unsealed radioactive material or significant quantities of sealed material, (4) radioactive waste brokers, (5) radioactive waste incinerators, (6) commercial nuclear laundries, and (7) any other application that in the judgement of the reviewer and cognizant supervisor involves complex technical issues, complex safety questions, or unprecedented issues that warrant a site visit.	N
C. The applicant requested certain radionuclides and quantities that equal or exceed the Risk Significant Quantity (TBq) values in the table, below, that have been "highlighted" by the reviewer	N

Table of Risk Significant Quantities

(Category 2 Quantities, IAEA Safety Guide No. RS-G-1.9, Categorization of Radioactive Sources, August 2005)

Radionuclide	Risk Significant Quantity (TBq ¹)	Risk Significant Quantity (Ci ¹)	Radionuclide	Risk Significant Quantity (TBq ¹)	Risk Significant Quantity (Ci ¹)
Am-241	0.6	16	Pm-147	400	11,000
Am-241/Be	0.6	16	Pu-238	0.6	16
Cf-252	0.2	5.4	Pu-239/Be	0.6	16
Cm-244	0.5	14	Ra-226 ²	0.4	11
Co-60	0.3	8.1	Se-75	2	54
Cs-137	1	27	Sr-90 (Y-90)	10	270
Gd-153	10	270	Tm-170	200	5,400
Ir-192	0.8	22	Yb-169	3	81

¹ The primary values are TBq. The curie (Ci) values are for informational purposes only.

² The Atomic Energy Act, as amended by the Energy Policy Act of 2005, authorizes NRC to regulate Ra-226 and NRC is in the process of amending its regulations for discrete sources of Ra-226.

Calculations of the Total Activity or the Unity Rule are attached to document whether or not the screening criteria in Step 2 were also completed to evaluate the application. NOTE—If an amendment of an existing license is being requested, the calculations will include the previously authorized quantities for the radionuclide(s).	Yes, No, or Not Applicable (NA)
Total Activity—multiple activities are requested for a single radionuclide and the sum of the activities equals or exceeds the quantity of concern for the radionuclide	—
Unity Rule—multiple radionuclides are requested and the sum of the ratios equals or exceeds unity, e.g., [(total activity for radionuclide A) ÷ (risk significant quantity for radionuclide A)] + [(total activity for radionuclide B) ÷ (risk significant quantity for radionuclide B)] ≥ 1.0.	—

Signature and Date for Step 1:

 9-11-06


License Reviewer and Date

August 18, 2006

RECEIVED

AUG 25 2006

DNMS



PeaceHealth

Ketchikan
General Hospital

RJC

United States Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, Texas 76011-4005

Ketchikan General Hospital
License No. 50-19913-01
Docket No. 030-19521

To Whom It May Concern:

We, Ketchikan General Hospital, are requesting that the following Doctors are added as authorized users to our license. Attached are the current licenses for them.

Dr. Stephanie Telesetsky Young
Dr. Mathew John Thomson

Thank you,

Cody Davis RT (R,N)
Lead Technologist
Ketchikan General Hospital

3100 Tongass Ave.
Ketchikan, AK 99901-5794

Tel. (907) 225-5171



Oregon

Theodore R. Kulongoski., Governor

Department of Human Services
Office of Environmental Public Health
800 NE Oregon Street
Portland, OR 97232
(971) 673-0515 Emergency
(971) 673-0490
Fax (971) 673-0553
TTY-Nonvoice (971) 673-0372

July 18, 2006

Sacred Heart Medical Center
Mathews B. Fish, M.D., RSO
1255 Hilyard Street
Eugene, Oregon 97401

Reference: License Number **ORE-90270**
Amendment Number **87**
Docket Number **06-0399**

Dear Dr. Fish:

The enclosed amendment reflects changes to your radioactive materials license as requested in letter dated June 28, 2006. The authorized user information has been updated. For your convenience these changes have been printed in boldface.

Please review the enclosed document carefully and notify this office immediately if corrections are necessary. If you have questions concerning this license, please contact the Radioactive Materials Licensing Program.

Sincerely,

A handwritten signature in cursive script, appearing to read "Margaret Lut".

Margaret Lut, Health Physicist
Radioactive Materials Licensing Program
State of Oregon, Radiation Protection Services

ML/dlm
Enclosure

[If you wish this information in an alternate format, please contact David Murdza at (971) 673-0504].

STATE OF OREGON
 OREGON STATE HEALTH DIVISION
 DEPARTMENT OF HUMAN SERVICES

Page 1 of 5 Pages
 License No. ORE-90270
 Amendment Number 87

RADIOACTIVE MATERIALS LICENSE

Pursuant to the Radiation Control Act and the Oregon Rules for the Control of Radiation, and in reliance on statements and representations heretofore made by the Licensee designated below, a license is hereby issued authorizing such licensee to transfer, receive, possess and use the radioactive material(s) designated below; and to use such radioactive materials for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations, and orders now or hereafter in effect of the State Health Division and to any and all conditions specified below.

In accordance with letter dated June 28, 2006, Oregon Radioactive Materials License Number ORE-90270 is amended to read as follows:

1. Name	Licensee Sacred Heart Medical Center	3. License Number	ORE-90270
		4. Expiration Date	December 31, 2007
2. Address	1255 Hilyard Street Eugene, Oregon 97401	3. Reference Number	Medical Diagnostic/Therapy-QMP

	6. Radioactive materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
35.100	A. Any radioactive material identified in OAR 333-116-0300	A. Any radiopharmaceutical identified in OAR 333-116-0300	A. As needed.
35.200	B. Any radioactive material identified in OAR 333-116-0320	B. Any radiopharmaceutical identified in OAR 333-116-0320	B. As needed.
	C. Any radioactive material identified in OAR 333-116-0360	C. Any radiopharmaceutical identified in OAR 333-116-0360	C. 14.8 GBq (400 millicuries).
	D. Any radioactive material identified in OAR 333-116-0420	D. Any brachytherapy source identified in OAR 333-116-0420	D. 96.2 GBq (2,600 millicuries).
	E. Gadolinium-153	E. Sealed sources (North American Scientific Model 3601 or DuPont Merck Model NES-8412)	E. Six sources not to exceed 11.1 GBq (300 millicuries) each.
	F. Cesium-137	F. Sealed source (Isotope Products Laboratories Model HEG-137)	F. Two sources not to exceed 1.11 GBq (30 millicuries) each.
	G. Uranium, Depleted	G. Shielding material	G. 100 pounds.

STATE OF OREGON
 OREGON STATE HEALTH DIVISION
 DEPARTMENT OF HUMAN SERVICES
RADIOACTIVE MATERIALS LICENSE

Page 1 of 5 Pages
 License No. ORE-90270
 Amendment Number 87

Pursuant to the Radiation Control Act and the Oregon Rules for the Control of Radiation, and in reliance on statements and representations heretofore made by the Licensee designated below, a license is hereby issued authorizing such licensee to transfer, receive, possess and use the radioactive material(s) designated below; and to use such radioactive materials for the purpose(s) and at the place(s) designated below. This license is subject to all applicable rules, regulations, and orders now or hereafter in effect of the State Health Division and to any and all conditions specified below.

In accordance with letter dated June 28, 2006, Oregon Radioactive Materials License Number ORE-90270 is amended to read as follows:

1. Name	Licensor Sacred Heart Medical Center	3. License Number ORE-90270
		4. Expiration Date December 31, 2007
2. Address	1255 Hilyard Street Eugene, Oregon 97401	3. Reference Number Medical Diagnostic/Therapy-QMP

6. Radioactive materials (element and mass number)	7. Chemical and/or physical form	8. Maximum quantity licensee may possess at any one time
A. Any radioactive material identified in OAR 333-116-0300	A. Any radiopharmaceutical identified in OAR 333-116-0300	A. As needed.
B. Any radioactive material identified in OAR 333-116-0320	B. Any radiopharmaceutical identified in OAR 333-116-0320	B. As needed.
C. Any radioactive material identified in OAR 333-116-0360	C. Any radiopharmaceutical identified in OAR 333-116-0360	C. 14.8 GBq (400 millicuries).
D. Any radioactive material identified in OAR 333-116-0420	D. Any brachytherapy source identified in OAR 333-116-0420	D. 96.2 GBq (2,600 millicuries).
E. Gadolinium-153	E. Sealed sources (North American Scientific Model 3601 or DuPont Merck Model NES-8412)	E. Six sources not to exceed 11.1 GBq (300 millicuries) each.
F. Cesium-137	F. Sealed source (Isotope Products Laboratories Model HEG-137)	F. Two sources not to exceed 1.11 GBq (30 millicuries) each.
G. Uranium, Depleted	G. Shielding material	G. 100 pounds.
H. Iodine-131	H. I-131-6-B-iodomethylnorcholesterol (Univ. of Michigan NP-59)	H. 0.37 GBq (10 millicuries)
I. Fluorine-18	I. Fluoro-2-deoxy-D-glucose	I. As needed.

9. Authorized use.

- A. Medical use as described in OAR 333-116-0300.

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSE

Page 2 of 5 Pages
License No. ORE-90270
Amendment Number 87

Continued from Page 1

- 9. Authorized use. (cont.)
 - B. Medical use as described in OAR 333-116-0320.
 - C. Medical use as described in OAR 333-116-0360.
 - D. Medical use as described in OAR 333-116-0420.
 - E. To be used, two sources per camera, in ADAC Laboratories SPECT or MCD/AC camera systems for patient transmission determination.
 - F. To be used in ADAC Laboratories MCD/AC camera system for attenuation corrections in FDG patient studies.
 - G. To be used as shielding in MCD/AC camera system.
 - H. To be used for adrenal gland imaging in accordance with License Condition 20 below.
 - I. Medical use as described in OAR 333-116-0320 for PET studies.

CONDITIONS

- 10. Licensed radioactive material shall be used only at the licensee's facilities located at 1255 Hilyard Street, Eugene, Oregon 97401.
- 11. This license is subject to and void without an annual validation certificate. Insofar as the licensee has submitted the proper fee prior to the expiration of a validation certificate, such existing validation certificate shall not expire until the issuance of a new validation certificate for the then current fiscal year.
- 12. The Radiation Safety Officer for the activities authorized by this license is Mathews B. Fish, M.D.
- 13. A. Licensed radioactive material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

<u>NAME</u>	<u>USE</u>
Charles McGlade, M.D.	Subitems A and B
Charles E. Deaton, M.D.	Subitems A and B
Lee G. Michels, M.D.	Subitems A and B
Cathryn L. Chicola, M.D.	Subitems A and B
L. Paul Wilson, M.D.	Subitems A and B
Tinko Zlatev, M.D.	Subitems A and B

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSE

Continued from Page 2

CONDITIONS (cont.)

- | (13.) A. | <u>NAME</u> | <u>USE</u> |
|----------|---|-------------------------------------|
| | Robert Gunderman, M.D. | Subitems A and B |
| | James D. Kippen, M.D. | Subitems A and B |
| | Bernardo Isuani, M.D. | Subitems A and B |
| | Philip J. Keizer, M.D. | Subitems A and B |
| | John D. Gorman, M.D. | Subitems A and B |
| | David W. Tsai, M.D. | Subitems A and B |
| | Stephen G. Thiede, M.D. | Subitems A and B |
| | John D. Grimme, M.D. | Subitems A and B |
| | Akshay S. Gupta, M.D. | Subitems A and B |
| | Stephanie Telesetsky Young, M.D. | Subitems A and B |
| | Matthew John Thomson, M.D. | Subitems A and B |
| | Michael S. Bullock, M.D. | Subitems C and D |
| | David Fryefield, M.D. | Subitems C, D and I |
| | Julie B. Gemmell, M.D. | Subitem D |
| | Richard C. Padgett, M.D. | Subitems E, F and G |
| | Gregory D. Kienzle, M.D. | Subitems A, B, E through G and I |
| | Jon Eckstrom, M.D. | Subitems A, B, E through G and I |
| | Rodger W. Shaver, M.D. | Subitems A, B, C, E through G and I |
| | Brent D. Kehn, M.D. | Subitems A, B, C, E through I |
| | Mathews B. Fish, M.D. | Subitems A, B, C, E through I |
| B. | Medical use of radioactive material as defined in OAR 333-116-0360, with the exception of iodine-131 for treatment of hyperthyroidism and thyroid carcinoma may also be used by Julie B. Gemmell, M.D. | |
| C. | Medical use of radioactive material as defined in OAR 333-116-0320, limited to cardiovascular clinical studies, may also be used by Richard C. Padgett, M.D. or David Saenger, M.D. | |
| 14. A. | Notwithstanding the requirement to prepare and use drugs in accordance with the package insert, if, in the judgment of the physician as authorized user, departures from the package insert, or use of unapproved drugs, is indicated, the physician may perform such procedures consistent with good professional medical practice as judged by the Oregon Board of Pharmacy, the Oregon Board of Medical Examiners, and/or the Oregon Radiation Advisory Board, as appropriate. | |

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSE

Page 4 of 5 Pages
License No. ORE-90270
Amendment Number 87

Continued from Page 3

CONDITIONS (cont.)

- (14.) B. Procedures shall be done by, or under the supervision of, persons whose training meets the requirements in OAR 333-116 and shall be in accordance with safe radiation safety procedures and ALARA in OAR 333-120. Radiopharmaceuticals shall not be used in humans until their pharmaceutical quality and assay have been established. Records documenting radioactive material used described in A. of this condition shall be kept by the licensee until inspection by the Agency.
- 15. Insofar as the licensee restricts the possession of radioactive material to quantities below the minimum limit specified in Appendix B of 10 CFR 30.35, the licensee is not required to provide financial assurance pursuant to OAR 333-102-0200 (6).
- 16. The licensee shall comply with requirements in OAR 333-120-0650 (records of internal dose) and OAR 333-102-0305(23) for materials stored for decay pursuant to OAR 333-116-0290.
- 17. Notwithstanding the requirements of OAR 333-116-0380(1)(h), the licensee is exempt from the bioassay requirement for I-131 therapeutic doses, when administered to patients in capsule form, pursuant to the one-year bioassay assessment results in application dated December 27, 2002.
- 18. The licensee is authorized to receive, possess and use as reference and calibration sources:
 - A. Sealed sources of radioactive material containing cobalt-57 not to exceed 20 millicuries.
 - B. Sealed sources of radioactive material with a half-life longer than 100 days in individual amounts not to exceed 1 millicurie.
 - C. Technetium-99m in individual amounts not to exceed 50 millicuries.
- 19. Notwithstanding the requirements in OAR 333-120-0180 and pursuant to the requirements in 333-116-0260, the licensee is authorized to release a patient who has been administered therapeutic radiopharmaceuticals or permanent implants containing radioactive material if the total effective does equivalent (TEDE) to any other individual is not likely to exceed 500 mrem. Upon release, the licensee shall:
 - (1) Provide the patient with written instructions to maintain doses to other individuals as low as reasonably achievable if the TEDE to any other individual is likely to exceed 5 millisieverts (0.5 rem);
 - (2) Maintain, for three years after the date of release, a record of the basis for authorizing patient release if the TEDE is calculated:
 - A. using the retained activity rather than the activity administered
 - B. using an occupancy factor less than 0.25 at 1 meter
 - C. using the biological or effective half-life, or

STATE OF OREGON
DEPARTMENT OF HUMAN SERVICES
HEALTH SERVICES
RADIOACTIVE MATERIALS LICENSE

Page 5 of 5 Pages
License No. ORE-90270
Amendment Number 87


Continued from Page 4

CONDITIONS (cont.)

- (19.) (2) D. considering shielding by tissue
- (3) Maintain a record, for three years after the date of release, showing that instructions were provided to a breast-feeding woman if the radiation dose to the infant or child from continued breast-feeding could result in a TEDE exceeding 5 millisieverts (0.5 rem).
- 20. Except as specifically provided otherwise by this license, the licensee shall conduct its program in accordance with statements, representations and procedures contained in the documents, including any enclosures listed below. The Oregon Rules for the Control of Radiation shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the rules.
 - A. Application dated December 27, 2002, signed by Jill Hoggard Greer, RN, Ph.D.
 - B. Letter dated February 27, 2003, signed by Mathews B. Fish, M.D.
 - C. E-mail correspondence dated May 27, 2003, from Elaine Stec, Nuclear Medicine Manager.
 - D. E-mail correspondence dated June 16, 2003, from Elaine Stec, Nuclear Medicine Manager.
 - E. E-mail correspondence dated June 30, 2003, from Elaine Stec, Nuclear Medicine Manager.
 - F. Letter dated February 9, 2004, signed by Mathews B. Fish, M.D., Medical Director.
 - G. Letter dated July 15, 2004, signed by Mathews B. Fish, M.D.
 - H. Letters (2) dated December 2, 2004, signed by Mathews B. Fish, M.D., Medical Director, Department of Nuclear Medicine, Radiation Safety Officer.
 - I. Letter dated February 22, 2005, signed by Mathews B. Fish, M.D., Radiation Safety Officer.
 - J. Letter dated July 20, 2005, signed by Mathews B. Fish, M.D., Radiation Safety Officer.
 - K. Letter dated June 28, 2006, signed by Mathews B. Fish, M.D., Radiation Safety Officer.

Date: July 18, 2006

FOR DHS PUBLIC HEALTH DIVISION

By 

Danny D. Loomis, Manager
Radioactive Materials Licensing Program

9-13-06
DATE

This is to acknowledge the receipt of your letter/application dated 8-18-06, and to inform you that the initial processing, which includes an acceptance review, has been performed.

There were no administrative omissions. Your application will be assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card:

The action you requested is normally processed in — days.

A copy of your action has been forwarded to the NRC Office of the Chief Financial Officer, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 471099.

When you call to inquire about this action, please refer to this mail control number.

You may call me at 817-860-8103.

Sincerely,
Colleen Murahan
Licensing Assistant




Ketchikan General Hospital


PeaceHealth

NewMed

3100 Tongass Avenue
Ketchikan, Alaska 99901

U.S. NRC
Region IV
611 Ryan Plaza Dr, Ste 400
Arlington, Texas 76011-4005





PeaceHealth

Ketchikan
General Hospital


Memo To: Radiation Safety Officer
From: Administration
Subject: Delegation of Authority
Date: September 11, 2006

You, Loulie Molloy MD, have been appointed Radiation Safety Officer. You are responsible for ensuring the safe use of radiation. You are responsible for managing the radiation protection program; identifying radiation protection problems; initiating, recommending, or providing corrective actions; verifying implementation of corrective actions; stopping unsafe activities; and ensuring compliance with regulations. You are hereby delegated the authority necessary to meet those responsibilities, including prohibiting the use of byproduct material by employees who do not meet the necessary requirements and shutting down operations where justified by radiation safety. You are required to notify management if staff do not cooperate and do not address radiation safety issues. In addition, you are free to raise issues with the Nuclear Regulatory Commission at any time.



Signature of Management Representative

I accept the above responsibilities,



(RSO)
cc: Nuclear Imaging Department, Clyde Pearce

4100 Tongass Ave.
Ketchikan, AK 99901-5794


Tel. (907) 225-5171

September 11, 2006

RECEIVED

SEP 18 2006

DNMS



PeaceHealth

Ketchikan
General Hospital

RTC
United States Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, Texas 76011-4005

Cc: Clyde Pearce, State of Alaska

Ketchikan General Hospital
License No. 50-19913-01
Docket No. 030-19521

To Whom It May Concern:

Ketchikan General Hospital is requesting an amendment to our license to show Loulie B. Molloy, M.D. as our new Radiation Safety Officer. Dr Cathryn Chicola will no longer be acting in this role effective 9/11/2006.

Thank you.

Cody Davis RT (R,N)
Lead Technologist
Ketchikan General Hospital



3100 Tongass Ave.
Ketchikan, AK 99901-5794

Tel. (907) 225-5171



Ketchikan General Hospital
PerceHealth
NucMed
 3100 Tongass Avenue
 Ketchikan, Alaska 99901

USNRC Region IV
 611 Ryan Plaza Dr, Ste 400
 Arlington, Texas 76011-4005



BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)

INFORMATION FROM LTS

: : : : :
: Program Code: 02121
: Status Code: 0
: Fee Category: 7C
: Exp. Date: 20120831
: Fee Comments: CODE 23
: Decom Fin Assur Reqd: N
: : : : :
: : : : :

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED

Applicant/Licensee: KETCHIKAN GENERAL HOSPITAL
Received Date: 20060825
Docket No: 3019521
Control No.: 471099
License No.: 50-19913-01
Action Type: Notifications

2. FEE ATTACHED

Amount: _____
Check No.: _____

3. COMMENTS

Signed *Allen M. ...*
Date _____

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / __/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:
Amendment _____
Renewal _____
License _____

3. OTHER _____

Signed _____
Date _____